Bank Of New York Mellon Corp Amylyx Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$27.71 - $40.93 $5.67 Million - $8.38 Million	204,656 New	204,656 $6 Billion
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $6.25 Million - $8.25 Million	210,139 New	210,139 $7.76 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $1.51 Million - $2.72 Million	87,923 Added 302.96%	116,944 $3.29 Million
Q2 2022 Aug 15, 2022	BUY	$6.85 - $19.93 $17,604 - $51,220	2,570 Added 9.72%	29,021 $558,000
Q1 2022 May 11, 2022	BUY	$12.85 - $32.9 $339,895 - $870,237	26,451 New	26,451 $340,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $237M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.